First Trust Advisors’s Ascendis Pharma A/S ASND Stock Holding History

First Trust Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.33M	Sell	16,226 -14,909	-48%	-$3.48M	﹤0.01%	1660
2026 Q1	$7.12M	Buy	31,135 +18,905	+155%	+$4.24M	0.01%	1258
2025 Q4	$2.61M	Buy	12,230 +5,269	+76%	+$1.09M	﹤0.01%	1757
2025 Q3	$1.38M	Buy	+6,961	New	+$1.3M	﹤0.01%	1992
2024 Q4	–	Sell	-5,887	Closed	-$879K	–	2561
2024 Q3	$879K	Buy	5,887 +955	+19%	+$129K	﹤0.01%	2037
2024 Q2	$673K	Buy	+4,932	New	+$671K	﹤0.01%	2057
2023 Q1	–	Sell	-3,602	Closed	-$440K	–	2356
2022 Q4	$440K	Buy	3,602 +1,251	+53%	+$145K	﹤0.01%	2226
2022 Q3	$243K	Buy	+2,351	New	+$223K	﹤0.01%	2369
2021 Q1	–	Sell	-19,683	Closed	-$3.28M	–	2413
2020 Q4	$3.28M	Buy	+19,683	New	+$3.25M	﹤0.01%	1323
2019 Q3	–	Sell	-1,867	Closed	-$215K	–	2395
2019 Q2	$215K	Buy	+1,867	New	+$223K	﹤0.01%	2345

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

First Trust Advisors's ASND Position: Q2 2026 in Review

First Trust Advisors reduced its Ascendis Pharma A/S (ASND) stake by 48% in Q2 2026, selling an estimated $3.48M and leaving 16,226 shares worth $4.33M. The position accounts for ﹤0.01% of the portfolio, ranked #1660.

First Trust Advisors first reported a position in ASND in Q2 2019 and has held it in 10 quarters since. The position peaked at $7.12M in Q1 2026. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

First Trust Advisors held 16,226 shares of Ascendis Pharma A/S worth $4.33M as of Q2 2026.
First Trust Advisors sold 14,909 Ascendis Pharma A/S shares in Q2 2026, an estimated $3.48M.
Ascendis Pharma A/S made up ﹤0.01% of First Trust Advisors's portfolio in Q2 2026, its #1660 holding.
First Trust Advisors first reported a position in Ascendis Pharma A/S in Q2 2019 and has held it in 10 quarters since.
First Trust Advisors's Ascendis Pharma A/S position peaked at $7.12M in Q1 2026.
311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.